NYSE:BSXBoston Scientific Stock Price, Forecast & News

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BSX stock has increased by 5.1% and is now trading at $35.59. View which stocks have been most impacted by Coronavirus.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 19 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Boston Scientific.

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Boston Scientific.

Boston Scientific will be holding an earnings conference call on Wednesday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Boston Scientific Co. (NYSE:BSX) announced its quarterly earnings results on Wednesday, April, 29th. The medical equipment provider reported $0.28 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.33 by $0.05. The medical equipment provider earned $2.54 billion during the quarter, compared to analysts' expectations of $2.54 billion. Boston Scientific had a net margin of 39.75% and a return on equity of 18.24%. The business's quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.35 EPS. View Boston Scientific's earnings history.

24 Wall Street analysts have issued 12-month target prices for Boston Scientific's stock. Their forecasts range from $25.00 to $58.00. On average, they anticipate Boston Scientific's share price to reach $44.65 in the next twelve months. This suggests a possible upside of 25.5% from the stock's current price. View analysts' price targets for Boston Scientific.

News articles about BSX stock have trended negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Boston Scientific earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Boston Scientific.

Some companies that are related to Boston Scientific include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE), Insulet (PODD) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Bank of America (BAC), CVS Health (CVS), salesforce.com (CRM), Johnson & Johnson (JNJ), AT&T (T), Home Depot (HD) and Visa (V).

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Boston Scientific's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%), Fulton Bank N. A. (0.00%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%), Modus Advisors LLC (0.00%) and Ellevest Inc. (0.00%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Williamson Scott, Xin Warren Wang and Yoshiaki Fujimori. View institutional ownership trends for Boston Scientific.

BSX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, and Wendy Carruthers. View insider buying and selling activity for Boston Scientific.

BSX stock was bought by a variety of institutional investors in the last quarter, including Fulton Bank N. A., Nelson Van Denburg & Campbell Wealth Management Group LLC, Ellevest Inc., and Modus Advisors LLC. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu, and Williamson Scott. View insider buying and selling activity for Boston Scientific.

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BSX stock can currently be purchased for approximately $35.59.

Boston Scientific has a market capitalization of $49.80 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 36,000 workers across the globe.

The official website for Boston Scientific is www.bostonscientific.com.

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]